Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D | P28221 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4135883 | 0.89 | HTR1D (0.40) | HTR1DGRIN2BHTR1AHTR7FAAH | |
| SCHEMBL4145248 | 0.83 | GRIN2B (0.51) | HTR1DGRIN2BHTR1AHTR7FAAH | |
| SCHEMBL20890502 | 0.83 | GRIN2B (0.43) | HTR1DGRIN2BMAPTHTR1AHTR7 | |
| SCHEMBL4136629 | 0.82 | OPRM1 (0.44) | HTR1DGRIN2BHTR1AHTR7FAAH | |
| SCHEMBL4147479 | 0.82 | FYN (0.44) | HTR1DGRIN2BHTR1AHTR7FAAH | |
| SCHEMBL4141143 | 0.82 | OPRM1 (0.44) | HTR1DGRIN2BHTR1AHTR7FAAH | |
| SCHEMBL4132535 | 0.82 | OPRM1 (0.44) | HTR1DGRIN2BHTR1AHTR7FAAH | |
| SCHEMBL4148545 | 0.82 | HTR1A (0.44) | HTR1DGRIN2BHTR1AHTR7FAAH | |
| SCHEMBL4135445 | 0.82 | ALDH1A1 (0.47) | HTR1D | |
| SCHEMBL4141014 | 0.82 | ALDH1A1 (0.47) | HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
| EP-2007749-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | Pfizer Products Inc. (US) | 2008-12-31 | — | — | EP | claimed |
| WO-2007105053-A2 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | PFIZER PRODUCTS INC. (US) | 2007-09-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | HTR1D 25/4885GRIN2B 86/4885SLC6A4 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.